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gested by these clinical experts. The resulting health states (n =
17) were piloted and used in a societal-based valuation study 
(n = 100). Participants rated half of the total health states in a
standard gamble interview to derive health state utility scores.
Data were analysed using a mixed model analysis. This study
was conducted in line with standard NICE appraisal methodol-
ogy. RESULTS: All tumour response statuses and toxicities were
independent signiﬁcant predictors of utility (p < 0.001). Stable
disease with no toxicity (our base state) had a utility value of
0.65. Utility scores ranged from 0.67 (responding disease with
no toxicity) to 0.47 for progressive disease. CONCLUSION:
This study reﬂects the value that society places on the avoidance
of disease progression and severe toxicities associated with the
treatment of second-line advanced NSCLC.
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OBJECTIVES: Assess inter-rater agreement (patient and parent)
of HUI utility scores for survivors of brain tumors in childhood.
METHODS: Patients and their parents were interviewed twice
using an interviewer-administered HUI questionnaire. Agree-
ment was assessed using intra-class correlation coefﬁcients
(ICC). T-tests assessed the statistical signiﬁcance of differences in
mean overall and pain utility scores between patients reporting
no pain and those reporting pain. RESULTS: HUI data for 40
brain tumor survivors (57.5% female) were collected during late
2000 and early 2001 (interview 1). To date, 26 re-assessment
interviews have been completed during 2005–2006 (interview 2).
One patient has died. Patient mean age was 6.8 years at diag-
nosis and 16.2 years at the ﬁrst survey. For overall health-related
quality of life scores (HRQL), there was substantial inter-rater
agreement (HUI3 ICC = 0.723, p < 0.001) at interview 1 and
moderate agreement (HUI3 ICC = 0.561, p = 0.03) at interview
2. There was substantial to almost perfect agreement at both
interviews for attributes considered readily observable (vision,
speech, ambulation and dexterity) (ICC 0.783 to 0.988, p <
0.001). For less observable attributes (emotion, cognition, pain),
agreement was moderate or less (ICC from 0.101 to 0.611, p =
0.372 to 0.002). Statistically signiﬁcant differences were detected
for both mean HRQL (difference = 0.36, p = 0.003) and pain
(difference = 0.24, p = 0.003) scores between patients reporting
pain (n = 14) and those pain free at interview 1. At interview 2,
the mean scores were not statistically signiﬁcantly different
between patients reporting pain (n = 7) and those with no pain
(n = 19, HRQL p = 0.317; pain attribute p = 0.067). CON-
CLUSIONS: There was moderate or better inter-rater agreement
for HRQL and all readily observable single-attribute HUI3
scores both at interview 1 and interview 2. Levels of ICC are
consistent with previous studies of childhood cancer survivors in
Brazil and Uruguay. Differences in mean HRQL and pain scores
between patients with and without pain is evidence of discrimi-
native validity.
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OBJECTIVES: Assess the reliability and validity of a newly
developed patient-reported outcome (PRO) questionnaire for
metastatic colorectal cancer (mCRC) patients. METHODS: The
questionnaire, which includes ﬁve scales [NCCN/FACT Col-
orectal Cancer Scale (CS), De Novo Bother Life Quality Index
(DNB), EORTC QLQ-C30 Global Quality of Life Subscale
(EORTC), EQ-5D Index Scale (EQ-5D) and the EQ-5D visual
analog scale (VAS)], was administered every four weeks to
mCRC patients in a Phase III clinical trial. Its psychometric prop-
erties were evaluated, including internal consistency reliability,
test-retest reliability, construct validity, known groups validity,
and responsiveness. RESULTS: A total of 391 mCRC patients
completed the questionnaire at baseline and at least one follow-
up assessment. Internal consistency was demonstrated with
Cronbach’s alphas for all scales >0.70 (range: 0.81–0.92). The
4-week test-retest reliability, as measured by the intra-class 
correlation, among patients who had stable EQ-5D scores and
also among patients whose ECOG performance status was
unchanged, ranged from 0.58–0.76 and 0.61–0.76, respectively.
Construct validity was demonstrated based on proposed inter-
scale correlations being borne out [e.g., CS was highly correlated
with EORTC (0.72)]. Known groups validity was evaluated by
examining the scale scores of patients categorized by their ECOG
performance status. Other than DNB, patients with better per-
formance status reported better scores than those with a lower
performance status (ECOG = 0 or 1 vs. 2). Signiﬁcant differences
were reported on all scales (p < 0.001) at baseline and week 8
with the exception of DNB. Responsiveness, as measured by
Guyatt’s statistic, was >0.20 for all scales from baseline to week
8 (range 0.56–1.13) and from weeks 4 to 12 (range 0.29–1.11).
EORTC and EQ-5D Index scales were the most responsive.
CONCLUSIONS: Results provide preliminary evidence of the
reliability, validity, and responsiveness of the questionnaire.
Additional work is needed to estimate the minimal clinical
important difference and more fully investigate test-retest 
reliability.
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OBJECTIVE: We examined demographics, clinical characteris-
tics, Health Related Quality of Life (HRQoL) and satisfaction
with care across two treatments (radical prostatectomy or RP
and external beam radiation or EBRT) for older prostate cancer
(PCa) patients. METHODS: In this prospective cohort study we
recruited 215 newly diagnosed PCa patients, 65 years or older,
from the urology clinics of an urban academic hospital and a VA
hospital. Patients completed generic (SF-36), prostate speciﬁc
(UCLA-PCI) HRQoL, and satisfaction with care (CSQ-8)
surveys prior to treatment and at 3, 6, and 12 months post-
treatment. Clinical and demographic data were obtained using
hospital based databases. Repeated measures ANOVA was used
to examine changes in generic and PCa speciﬁc HRQoL across
treatments. Log-linear regression was used to determine factors
associated with 12 month HRQoL. Survival curves were used to
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compare return to baseline (RTB) for HRQoL. A seven point dif-
ference (considered to be clinically signiﬁcant) between baseline
and follow-up score was considered as RTB. RESULTS: ANOVA
indicated that RP group had higher scores for generic HRQoL
subscales of physical function (p = 0.019), role emotional (p =
0.037), vitality (p = 0.033) and general health (p = 0.05). Step-
wise log-linear regression models showed that RP was associated
with higher 12 month scores for most of the generic HRQoL
scales, bowel function (OR = 1.12), urinary bother (OR = 1.6)
and bowel bother (OR = 1.5). For generic HRQoL (SF-36) at 12
month follow-up, higher proportion of the RP group returned to
baseline on eight sub-scales. RP group had lower proportion
returning to baseline for urinary (p = 0.0012) and sexual (p =<
0.0001) functions, and higher proportion returning to baseline
for bowel function, urinary bother and bowel bother (p =<
0.005). Satisfaction with care was comparable between treat-
ment groups. CONCLUSIONS: Older patients appear to have
better tolerance for RP as indicated by patient reported 
outcomes. Thus age alone need not be a criterion in treatment
decision.
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OBJECTIVE: To compare self-reported satisfaction with care
and emotional well-being of newly diagnosed prostate cancer
(PCa) patients receiving either Radical Prostatectomy (RP) or
External Beam Radiation Therapy (EBRT). METHODS: The
study was part of a larger prospective cohort study. We recruited
231 newly diagnosed African-American and Caucasian PCa
patients from urology clinics of an urban academic hospital and
a VA hospital. Patients completed the Client Satisfaction Ques-
tionnaire (CSQ-8), SF-36, FACT-p and UCLA-PCI prior to their
treatment and at 3, 6, and 12 month follow-up. Demographic
and clinical data were obtained from hospital based databases.
Parametric and nonparametric tests were used to compare demo-
graphics, clinical characteristics and FACT-p subscales between
treatment groups. Log linear regression models were used to
assess factors associated with satisfaction. RESULTS: The RP
group was younger (p < 0.0001), had a higher proportion of
Caucasians (p < 0.0001), and were more like to be married (p <
0.0001), have incomes greater than $40,000 (p < 0.0001) and
be employed full-time (p < 0.0001). Gleason score, TNM stage
and Charlson comorbidity score were comparable by groups.
Higher number of EBRT group reported poorer outcome mea-
sures on emotional well being subscale of FACT-p, compared to
RP group. A higher proportion of RP patients indicated that they
were likely to recommend the treatment to a friend (p = 0.0244)
and that they would seek the same treatment if needed again 
(p = 0.0328). ANOVA of total CSQ8 score indicated signiﬁcant
differences between the groups and over time (p = 0.0059 and
0.0228, respectively). Log linear regression showed that RP
treatment (OR = 1.13, p = 0.045), baseline PSA (OR = 0.98, 
p = 0.0062) and VA hospital (OR = 0.84, p = 0.0299) were asso-
ciated with total satisfaction with care. CONCLUSION: EBRT,
higher baseline PSA and non-VA hospital type are associated
with lower satisfaction with care of PCa patients at 12 months
post-treatment.
PCN74
UTILITIES ASSOCIATED WITH NON-SMALL CELL LUNG
CANCER (NSCLC): A COMMUNITY STUDY
Tabberer M1, Stamuli E1,Walker M2, Summerhayes M2, Lees M1
1Oxford Outcomes Ltd, Oxford, Oxon, UK, 2Roche Products Ltd,
Welwyn Garden City, Herts, UK
OBJECTIVE: Exploring impact of NSCLC on quality of life
(QOL) by eliciting utilities from a community sample. Non-small
cell lung cancer (NSCLC) and its treatment both have a sub-
stantial negative effect on QOL. Little published research quan-
tiﬁes these effects in advanced disease. METHODS: Health state
descriptions were developed from the literature and reﬁned
through clinician interviews (n = 6). Treatment response, stable
disease, progressed disease, near-death and adverse events (AEs):
neutropenia, febrile neutropenia, nausea, diarrhoea, stomatitis,
neuropathy and rash were described. The impact of oral versus
intravenous (IV) medication was also explored. A total of 154
lay people across the UK (Glasgow, Oxford, London, Cardiff)
were presented with information on NSCLC. Health states, pre-
sented randomly, were valued using the EQ-5D. These values
were converted to utilities for each health state. RESULTS: All
health states were associated with low utility values. The utility
value for near-death was the lowest (0.15) and that for treatment
response the highest (0.49). There was no statistical difference
between treatment response and stable disease (0.46). Stable
disease receiving IV therapy had a signiﬁcantly lower utility
(0.43) than stable disease with no treatment; stable disease
receiving oral therapy (0.45) did not. The utility value associated
with progressed disease (0.22) was closer to that for near-death.
Utilities for AEs were valued relative to the stable disease state.
The greatest disutility was associated with febrile neutropenia 
(−0.27) and the lowest with rash (−0.06). Disutilities associated
with other AEs were neuropathy (−0.15), neutropenia (−0.14),
nausea (−0.14), stomatitis (−0.14) and diarrhoea (−0.13). CON-
CLUSIONS: Societal valuation showed that all disease states and
AEs associated with NSCLC have a substantial impact on QOL,
with disease progression, febrile neutropenia and near-death
having the greatest impact. Treatment related rash is the least
serious adverse event. Stable disease is associated with a better
QOL than progressed disease.
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OBJECTIVES: Human Papillomavirus (HPV) is a necessary
cause of cervical cancer (CC). To date, CC screening programmes
have been the only tool to help to prevent CC by detecting and
removing precancerous lesions. With the expected licensure of a
quadrivalent HPV vaccination, a decision analysis model was
developed to quantify the health and economic beneﬁts of a
quadrivalent (6, 11, 16, 18) HPV vaccine alongside CC screen-
ing in Switzerland. METHODS: The vaccine was considered to
prevent 100% of HPV 6, 11, 16 and 18-associated diseases, with
lifetime duration of protection and 40% coverage rate, when
given to girls at age 12. Resource consumption included physi-
cian visits, medical examinations, treatments and hospitalisa-
tions. Data for management of abnormal pap smears, cervical
dysplasia and genital warts were estimated by Swiss experts.
